Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
46
THAR Quote, Financials, Valuation and Earnings
Last price:
$2.90
Seasonality move
:
50.79%
Day range:
$2.60 - $2.89
52-week range:
$0.95 - $9.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
16.06x
Volume:
748.6K
Avg. volume:
377.1K
1-year change:
36.89%
Market cap:
$98.8M
Revenue:
--
EPS (TTM):
-$3.91
Analysts' Opinion
-
Consensus RatingTharimmune, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.00, Tharimmune, Inc. has an estimated upside of 77.31% from its current price of $2.82.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $2.82.
Fair Value
-
According to the consensus of 1 analyst, Tharimmune, Inc. has 77.31% upside to fair value with a price target of $5.00 per share.
THAR vs. S&P 500
-
Over the past 5 trading days, Tharimmune, Inc. has overperformed the S&P 500 by 22.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Tharimmune, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tharimmune, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Tharimmune, Inc. reported revenues of --.
Earnings Growth
-
Tharimmune, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Tharimmune, Inc. reported earnings per share of -$0.34.
Enterprise value:
91.4M
EV / Invested capital:
14.39x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-10.48x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-247.3%
Net Income Margin (TTM):
--
Return On Equity:
-514.29%
Return On Invested Capital:
-462.2%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$8.7M | -$11.1M | -$10.3M | -$3.9M | -$2.1M | |
| EBITDA | -$8.7M | -$11.1M | -$10.3M | -$3.9M | -$2.1M | |
| Diluted EPS | -$243.17 | -$10.91 | -$3.91 | -$2.45 | -$0.34 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $49K | $7.8M | $3.1M | $5.1M | $7.7M | |
| Total Assets | $414.9K | $7.8M | $3.2M | $5.3M | $7.7M | |
| Current Liabilities | $6.6M | $716.7K | $1.4M | $2.2M | $1.5M | |
| Total Liabilities | $7.6M | $716.7K | $1.4M | $2.2M | $1.5M | |
| Total Equity | -$7.1M | $7.1M | $1.8M | $3M | $6.2M | |
| Total Debt | $2.2M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.9M | -$9.3M | -$8.7M | -$2.9M | -$1.9M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $2M | $11.4M | $11.6M | -$257.7K | $7.2M | |
| Free Cash Flow | -$6.9M | -$9.3M | -$8.7M | -$2.9M | -$1.9M | |
THAR
Sector
Market Cap
$98.8M
$27.9M
Price % of 52-Week High
31.06%
50.56%
Dividend Yield
0%
0%
Shareholder Yield
-64.41%
-1.55%
1-Year Price Total Return
36.89%
-17.49%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.48
200-day SMA
Buy
Level
$2.22
Bollinger Bands (100)
Sell
Level
1.95 - 4.05
Chaikin Money Flow
Sell
Level
-245.7K
20-day SMA
Buy
Level
$2.47
Relative Strength Index (RSI14)
Buy
Level
58.07
ADX Line
Buy
Level
20.89
Williams %R
Sell
Level
-10.1449
50-day SMA
Buy
Level
$2.80
MACD (12, 26)
Buy
Level
0.72
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
1.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-23.527)
Sell
CA Score
(Annual)
Level (-7.1368)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (16.4942)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Stock Forecast FAQ
In the current month, THAR has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The THAR average analyst price target in the past 3 months is $5.00.
-
Where Will Tharimmune, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tharimmune, Inc. share price will rise to $5.00 per share over the next 12 months.
-
What Do Analysts Say About Tharimmune, Inc.?
Analysts are divided on their view about Tharimmune, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tharimmune, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Tharimmune, Inc.'s Price Target?
The price target for Tharimmune, Inc. over the next 1-year time period is forecast to be $5.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is THAR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tharimmune, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of THAR?
You can purchase shares of Tharimmune, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tharimmune, Inc. shares.
-
What Is The Tharimmune, Inc. Share Price Today?
Tharimmune, Inc. was last trading at $2.90 per share. This represents the most recent stock quote for Tharimmune, Inc.. Yesterday, Tharimmune, Inc. closed at $2.82 per share.
-
How To Buy Tharimmune, Inc. Stock Online?
In order to purchase Tharimmune, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get THAR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
THAR
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
16.06x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
THAR
Sector
Revenue growth
--
4.6%
Earnings growth
86.28%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.21
Profitability
THAR
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-462.2%
-31.84%
Return on assets
-247.3%
-27.96%
Return on equity
-514.29%
-37.63%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Dec
30
Estimated Next Earnings Date
Mar
31
Balance Sheet
THAR
Sector
Total cash
$7.6M
$26.3M
Short term investments
--
$25.7M
Total assets
$3.7M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 36.69% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 4.26% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
